自体CIK细胞治疗晚期非小细胞肺癌

Efficacy of treating advanced non-small cell lung cancer with autologous cytokine-induced killer cells

目的研究自体细胞因子诱导的杀伤细胞(CIK)细胞联合化疗治疗晚期非小细胞的疗效。方法59例患者分成A组(单用TP方案化疗)与B组(自体CIK联合TP方案治疗)。对两组的生活质量、免疫学反应、缓解率(RR)、无疾病进展时间与生存期进行观察比较。CIK细胞由自体外周血单个核细胞扩增培养产生。结果CIK细胞的数量与杀伤活性均在培养第14～21天形成到高峰。与A组相比,B组病人的免疫力与生活质量显著提高。结论自体CIK联合化疗治疗晚期非小细胞肺癌能有效改善患者的免疫功能。

Objective To study the efficacy of treating advanced non-small cell lung cancer （NSCLC） with autologous cytokine-induced killer （CIK）cells combined with chemotherapy combined with biotherapy. Methods Fifty-nine advanced NSCLC patients were divited into group A （TP chemotherapy alone） and group B （TP chemotherapy plus autologous CIK biotherapy）. The quality of life, host cellular immune response, remission rate（RR）, time to progression and median survival time were investigated and compared between the two groups. CIK cells were induced from autologous peripheral mononuclear cells. Results Amounts and cytotoxic activity of CIK cells reached the peak level between days 14 to 21. Compared to group A, the host immune function and quality of life in group B were significantly improved. Conclusion Chemotherapy combined with CIK cells can effectively improve the immune function.